Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: A patent survey

Petra Dunkel, Balázs Balogh, Rita Meleddu, Elias MacCioni, K. Gyires, P. Mátyus

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Introduction: Vascular adhesion protein-1 (VAP-1)/semicarbazide-sensitive amine oxidase (SSAO) is an adhesion protein involved in leukocyte trafficking and inflammatory processes, with a special amine oxidase activity. Inhibitors have been mainly developed for treating chronic inflammatory disorders. The utility of inhibitors as antiangiogenic agents in ophthalmological and oncological diseases is currently under evaluation. SSAO substrates may mimic several insulin effects, although their utility for the treatment of diabetes is still far from being fully understood. Areas covered: This paper reviews the patent literature of SSAO/VAP-1 inhibitors and substrates, for the period of 1990 2010. The current stage of SSAO/VAP-1-interacting agents published in patents is described, along with their chemical structures and pharmacological uses. Expert opinion: SSAO/VAP-1 is a promising anti-inflammatory target. Another important field for therapeutic application of these inhibitors may be ophthalmology, due to their antiangiogenic effects. SSAO substrates might also be of therapeutic value in the treatment of diabetes; however, more extensive research has to be undertaken to validate this approach.

Original languageEnglish
Pages (from-to)1453-1471
Number of pages19
JournalExpert Opinion on Therapeutic Patents
Volume21
Issue number9
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Amine Oxidase (Copper-Containing)
Blood Vessels
Proteins
Patents
Angiogenesis Inhibitors
Expert Testimony
Ophthalmology
Amines
Surveys and Questionnaires
Oxidoreductases
Leukocytes
Anti-Inflammatory Agents
Pharmacology
Insulin
Therapeutics
Research

Keywords

  • Anti-inflammatory agents
  • Antiangiogenic agents
  • AOC2
  • AOC3
  • Diabetes
  • Semicarbazide-sensitive amine oxidase
  • Vascular adhesion protein-1

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 : A patent survey. / Dunkel, Petra; Balogh, Balázs; Meleddu, Rita; MacCioni, Elias; Gyires, K.; Mátyus, P.

In: Expert Opinion on Therapeutic Patents, Vol. 21, No. 9, 09.2011, p. 1453-1471.

Research output: Contribution to journalArticle

Dunkel, Petra ; Balogh, Balázs ; Meleddu, Rita ; MacCioni, Elias ; Gyires, K. ; Mátyus, P. / Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 : A patent survey. In: Expert Opinion on Therapeutic Patents. 2011 ; Vol. 21, No. 9. pp. 1453-1471.
@article{c7131bc97aff46b99c64b15a6fbf81eb,
title = "Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: A patent survey",
abstract = "Introduction: Vascular adhesion protein-1 (VAP-1)/semicarbazide-sensitive amine oxidase (SSAO) is an adhesion protein involved in leukocyte trafficking and inflammatory processes, with a special amine oxidase activity. Inhibitors have been mainly developed for treating chronic inflammatory disorders. The utility of inhibitors as antiangiogenic agents in ophthalmological and oncological diseases is currently under evaluation. SSAO substrates may mimic several insulin effects, although their utility for the treatment of diabetes is still far from being fully understood. Areas covered: This paper reviews the patent literature of SSAO/VAP-1 inhibitors and substrates, for the period of 1990 2010. The current stage of SSAO/VAP-1-interacting agents published in patents is described, along with their chemical structures and pharmacological uses. Expert opinion: SSAO/VAP-1 is a promising anti-inflammatory target. Another important field for therapeutic application of these inhibitors may be ophthalmology, due to their antiangiogenic effects. SSAO substrates might also be of therapeutic value in the treatment of diabetes; however, more extensive research has to be undertaken to validate this approach.",
keywords = "Anti-inflammatory agents, Antiangiogenic agents, AOC2, AOC3, Diabetes, Semicarbazide-sensitive amine oxidase, Vascular adhesion protein-1",
author = "Petra Dunkel and Bal{\'a}zs Balogh and Rita Meleddu and Elias MacCioni and K. Gyires and P. M{\'a}tyus",
year = "2011",
month = "9",
doi = "10.1517/13543776.2011.594040",
language = "English",
volume = "21",
pages = "1453--1471",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1

T2 - A patent survey

AU - Dunkel, Petra

AU - Balogh, Balázs

AU - Meleddu, Rita

AU - MacCioni, Elias

AU - Gyires, K.

AU - Mátyus, P.

PY - 2011/9

Y1 - 2011/9

N2 - Introduction: Vascular adhesion protein-1 (VAP-1)/semicarbazide-sensitive amine oxidase (SSAO) is an adhesion protein involved in leukocyte trafficking and inflammatory processes, with a special amine oxidase activity. Inhibitors have been mainly developed for treating chronic inflammatory disorders. The utility of inhibitors as antiangiogenic agents in ophthalmological and oncological diseases is currently under evaluation. SSAO substrates may mimic several insulin effects, although their utility for the treatment of diabetes is still far from being fully understood. Areas covered: This paper reviews the patent literature of SSAO/VAP-1 inhibitors and substrates, for the period of 1990 2010. The current stage of SSAO/VAP-1-interacting agents published in patents is described, along with their chemical structures and pharmacological uses. Expert opinion: SSAO/VAP-1 is a promising anti-inflammatory target. Another important field for therapeutic application of these inhibitors may be ophthalmology, due to their antiangiogenic effects. SSAO substrates might also be of therapeutic value in the treatment of diabetes; however, more extensive research has to be undertaken to validate this approach.

AB - Introduction: Vascular adhesion protein-1 (VAP-1)/semicarbazide-sensitive amine oxidase (SSAO) is an adhesion protein involved in leukocyte trafficking and inflammatory processes, with a special amine oxidase activity. Inhibitors have been mainly developed for treating chronic inflammatory disorders. The utility of inhibitors as antiangiogenic agents in ophthalmological and oncological diseases is currently under evaluation. SSAO substrates may mimic several insulin effects, although their utility for the treatment of diabetes is still far from being fully understood. Areas covered: This paper reviews the patent literature of SSAO/VAP-1 inhibitors and substrates, for the period of 1990 2010. The current stage of SSAO/VAP-1-interacting agents published in patents is described, along with their chemical structures and pharmacological uses. Expert opinion: SSAO/VAP-1 is a promising anti-inflammatory target. Another important field for therapeutic application of these inhibitors may be ophthalmology, due to their antiangiogenic effects. SSAO substrates might also be of therapeutic value in the treatment of diabetes; however, more extensive research has to be undertaken to validate this approach.

KW - Anti-inflammatory agents

KW - Antiangiogenic agents

KW - AOC2

KW - AOC3

KW - Diabetes

KW - Semicarbazide-sensitive amine oxidase

KW - Vascular adhesion protein-1

UR - http://www.scopus.com/inward/record.url?scp=80052066548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052066548&partnerID=8YFLogxK

U2 - 10.1517/13543776.2011.594040

DO - 10.1517/13543776.2011.594040

M3 - Article

C2 - 21675926

AN - SCOPUS:80052066548

VL - 21

SP - 1453

EP - 1471

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 9

ER -